Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
On March 21, 2026, major health and industry groups urged the FDA to clarify guidelines for Bayesian clinical trial methods to ensure transparency, rigor, and reproducibility.
On March 21, 2026, multiple organizations including EFSPI, the International Society of Pharmacoepidemiology, the Pediatric Inclusion Alliance, Regeneron Pharmaceuticals, BIO, and Insmed Inc. submitted public comments to the FDA on its draft guidance for Bayesian methods in clinical trials.
They urged clearer, more consistent regulatory expectations around model transparency, prior data use, and sensitivity analysis to ensure scientific rigor and reproducibility.
Supporters highlighted benefits such as improved trial efficiency, reduced patient burden, and better integration of existing evidence, particularly in pediatric and rare disease research.
The FDA is reviewing the feedback as part of its effort to modernize guidance on innovative trial designs.
El 21 de marzo de 2026, los principales grupos de salud e industria instaron a la FDA a aclarar las pautas para los métodos de ensayos clínicos bayesianos para garantizar la transparencia, el rigor y la reproducibilidad.